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Energy expenditureInterleukin-6 (IL-6) is a multifunctional protein and has a major inﬂuence on energy metabolism. The current
study was designed to assess the therapeutic effect of overexpression of Il-6 gene through gene transfer on
high fat diet-induced obese mice. Hydrodynamic delivery of 1 μg pLIVE-IL6 plasmid per mouse into C57BL/6
obesemice resulted inpeak level at 10ng/ml of circulating IL-6 1 day after gene transfer and above 1 ng/ml there-
after for a period of 6 weeks. Persistent Il-6 gene expression did not affect food intake but induced a signiﬁcant
reduction in body weight and improved obesity-associated hepatic steatosis. Il-6 gene delivery enhanced ther-
mogenic gene expression and elevated protein levels of phosphorylated STAT3, PGC1α and UCP1 in brown adi-
pose tissue. Il-6 overexpression elevated mRNA levels of lipolysis genes, triggered phosphorylation of STAT3,
AMPK, and ACC, and increased expression of genes involved in fatty acid oxidation in skeletal muscle. IL-6 did
not affect macrophage inﬁltration but maintained the M2macrophage population in adipose tissue. Collectively,
these results suggest that overexpression of the Il-6 gene by hydrodynamic gene delivery inducesweight loss and
alleviates obesity-induced fatty liver and insulin resistance, supporting the notion that gene transfer is a valid ap-
proach in managing obesity epidemics.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Interleukin-6 (IL-6), produced by immune and non-immune cells,
is a multifunctional cytokine. IL-6 is commonly known as a pro-
inﬂammatory cytokine that regulates immunoreaction and acute
immune response. More recent studies have shown that IL-6 has an
anti-inﬂammatory activity as it increases the production of IL-10, IL-1
receptor antagonist (IL-1ra), and soluble TNF-receptors [1–3]. In addi-
tion to modulating the immune system, IL-6 has also attracted particu-
lar attention for its pivotal role in regulating energy expenditure, body
composition and peripheral lipid metabolism [4–6].
The effects of IL-6 on nutrient homeostasis and obesity remain con-
troversial and unresolved. IL-6 is generally considered an obesity-
related inﬂammatory factor and mediator for insulin resistance as
elevated circulating IL-6 is correlated with adiposity and insulin resis-
tance in humans [7–9]. However, substantial evidence suggests that
IL-6 exerts a beneﬁcial inﬂuence in this context. Physical exercise
promotes secretion of IL-6 from skeletal muscle and the blood concen-
tration of IL-6 increases about 100-fold, improving insulin sensitivityutical and Biomedical Science,
South, 250 West Green Street,
06 542 5358.[10,11], while IL-6 knockout mice developed obesity, systemic insulin
resistance and inﬂammation [4,12], which could be partially reversed
by intra-cerebriventricular injection of the IL-6 protein [4]. Meanwhile,
direct delivery of adeno-associated viral vectors containing the Il-6 gene
into the rat hypothalamus or mice carrying the human Il-6 gene sup-
pressed weight gain and visceral adiposity [13,14], indicating that IL-6
exerts anti-obesity effects in rodents. Moreover, short-term intra-
cerebroventricular injections of the recombinant IL-6 protein and a pe-
ripheral increase in Il-6 gene expression induced weight loss and
improved insulin sensitivity inmice [15,16]. Although these studies sup-
port the potential application of IL-6 in ﬁghting obesity, the systemic ef-
fects of prolonged elevation of IL-6 level in obesemice remain unknown.
Here we preserve sustained Il-6 expression in obese mice by hydro-
dynamic gene delivery and demonstrate that long-termmaintenance of
IL-6 levels signiﬁcantly induced weight loss in obesemice by enhancing
lipolysis and energymetabolism, resulting in improved insulin sensitiv-
ity andmaintenance of glucose homeostasis as well as a reduction in fat
accumulation in the liver. Il-6 gene transfer did not affect macrophage
inﬁltration, but countered the obesity-related inﬂammatory signal by
enhancing the expression of M2 macrophage gene markers and related
anti-inﬂammatory factor genes. Our results indicate the long-term
beneﬁcial effects of IL-6 elevation on obesity and suggest the potential
application of Il-6 gene transfer as a means of controlling obesity and
obesity-related metabolic disorders.
Table 1
Primer sets for real time PCR analysis of gene expression.
Name Forward sequence Reverse sequence
Pparγ1 GGAAGACCACTCGCATTCCTT GTAATCAGCAACCATTGGGTCA
Pparγ2 TCGCTGATGCACTGCCTATG GAGAGGTCCACAGAGCTGATT
Cd36 CCTTAAAGGAATCCCCGTGT TGCATTTGCCAATGTCTAGC
Fabp4 AAGGTGAAGAGCATCATAACCC TCACGCCTTTCATAACACATTCC
Mgat1 TGGTGCCAGTTTGGTTCCAG TGCTCTGAGGTCGGGTTCA
Pparα TGTCGAATATGTGGGGACAA AATCTTGCAGCTCCGATCAC
Acox1 CCGCAACCTTCAATCCAGAG CAAGTTCTCGATTTCTCGACGG
Cpt1a CTCCGCCTGAGCCATGAAG CACCAGTGATGATGCCATTCT
Cpt1b GGTCTCTTCTTCAAGGTCTG CGAGGATTCTCTGGAACTGC
Srebp-1c CCCTGTGTGTACTGGCCTTT TTGCGATGTCTCCAGAAGTG
Acc-1 GCCTCTTCCTGACAAACGAG TGACTGCCGAAACATCTCTG
Fas AGAGATCCCGAGACGCTTCT GCCTGGTAGGCATTCTGTAGT
Scd-1 TTCTTACACGACCACCACCA CCGAAGAGGCAGGTGTAGAG
Cyp7a1 AACGGGTTGATTCCATACCTGG GTGGACATATTTCCCCATCAGTT
Hmgcr CTTGTGGAATGCCTTGTGATTG AGCCGAAGCAGCACATGAT
Pepck AAGCATTCAACGCCAGGTTC GGGCGAGTCTGTCAGTTCAAT
G6pase CGACTCGCTATCTCCAAGTGA GTTGAACCAGTCTCCGACCA
Insulin1 CACTTCCTACCCCTGCTGG ACCACAAAGATGCTGTTTGACA
Insulin2 GCTTCTTCTACACACCCATGTC AGCACTGATCTACAATGCCAC
Hsl GCTTGGTTCAACTGGAGAGC GCCTAGTGCCTTCTGGTCTG
Atgl CAACGCCACTCACATCTACGG TCACCAGGTTGAAGGAGGGAT
Ucp1 AGGCTTCCAGTACCATTAGGT CTGAGTGAGGCAAAGCTGATTT
Ucp2 GCGTTCTGGGTACCATCCTA GCTCTGAGCCCTTGGTGTAG
Ucp3 ATGAGTTTTGCCTCCATTCG GGCGTATCATGGCTTGAAAT
Pgc-1α GAAGTGGTGTAGCGACCAATC AATGAGGGCAATCCGTCTTCA
Pgc-1β TTGTAGAGTGCCAGGTGCTG GATGAGGGAAGGGACTCCTC
Dio2 AATTATGCCTCGGAGAAGACCG GGCAGTTGCCTAGTGAAAGGT
Cidea ATCACAACTGGCCTGGTTACG TACTACCCGGTGTCCATTTCT
Elovl3 TTCTCACGCGGGTTAAAAATGG GAGCAACAGATAGACGACCAC
F4/80 CCCCAGTGTCCTTACAGAGTG GTGCCAGAGTGGATGTCT
Cd68 CCATCCTTCACGATGACACCT GGCAGGGTTATGAGTGACAGTT
Cd11b ATGGACGCTGATGGCAATACC TCCCCATTCACGTCTCCCA
Cd11c ACGTCAGTACAAGGAGATGTTGGA ATCCTATTGCAGAATGCTTCTTTACC
Mcp-1 ACTGAAGCCAGCTCTCTCTTCCTC TTCCTTCTTGGGGTCAGCACAGAC
Tnfα CCCTCACACTCAGATCATCTTCT GCTACGACGTGGGCTACAG
Il-1β GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT
Cd163 TCCACACGTCCAGAACAGTC CCTTGGAAACAGAGACAGGC
Cd206 CAGGTGTGGGCTCAGGTAGT TGTGGTGAGCTGAAAGGTGA
Il-10 GCTCTTACTGACTGGCATGAG CGCAGCTCTAGGAGCATGTG
Il-4 GGTCAACCCCCAGCTAGT GCCGATGATCTCTCTCAAGTGAT
Il-4rα TCTGCATCCCGTTGTTTTGC GCACCTGTGCATCCTGAATG
Il-13 CCTGGCTCTTGCTTGCCTT GGTCTTGTGTGATGTTGCTCA
Il-13rα1 TCAGCCACCTGTGACGAATTT TGAGAGTGCAATTTGGACTGG
Acadl TCTTTTCCTCGGAGCATGACA CAGACCTCTCTACTCACTTCTCCAG
Gapdh AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA
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2.1. Plasmid construction
A mouse Il-6 open reading fragment was obtained from OriGene
(Rockville, MD) and reconstructed into a pLIVE plasmid vector (Mirus
Bio, Madison, WI) at the NheI and XhoI cutting sites. The insertion in
the new plasmid (pLIVE-IL6) was conﬁrmed using DNA sequencing.
The pLIVE-IL6 and empty plasmids were puriﬁed using CsCl–ethidium
bromide density-gradient ultracentrifugation and kept in saline
(0.9% sodium chloride). Purity of the plasmids was veriﬁed with absor-
bency ratio at 260 and 280 nm and by 1% agarose gel electrophoresis.
2.2. Animal treatment
C57BL/6 mice (male, 10-week old) were purchased from Charles
River Laboratories (Wilmington, MA) and housed under standard con-
ditions with a 12 h light–dark cycle. All procedures performed on ani-
mals were approved by the Institutional Animal Care and Use
Committee at the University of Georgia, Athens, Georgia. Obese mice
(50 ± 2 g) were developed by feeding animals for 20 weeks with high
fat diet (HFD) (60% kJ/fat, 20% kJ/carbohydrate, 20% kJ/protein, Bio-
Serv, Frenchtown,NJ). Regularmicewere fedwith a standard laboratory
chow diet (20% kJ/fat, 60% kJ/carbohydrate, 20% kJ/protein, LabDiet, St
Louis,MO). Food consumptionwas determined bymeasuring the differ-
ence between the amount provided and the amount left every three
days. Food intake per mouse was calculated based on the amount con-
sumed divided by time and the number of mice per cage. The procedure
for hydrodynamic gene delivery in obese mice was performed accord-
ing to an established procedure [17,18] with somemodiﬁcation. Brieﬂy,
an appropriate volume of saline solution (equivalent to 8% leanmass of
an obese mouse) containing 1 μg pLIVE-IL6 or empty plasmid was
injected through the tail vein within 5–8 s. Mice were continually fed
an HFD for 6 weeks. The body weight of each mouse was measured on
an electronic balance, and body composition was analyzed using
EchoMRI-100 (Echo Medical Systems, Houston, TX) once per week.
The same procedures were also performed on age-matched male mice
with chow feeding. Blood was collected at the desired time points
using a Microvette-CB300-LH from Fisher Scientiﬁc (Pittsburgh, PA)
and plasma IL-6 concentrations were determined using ELISA kits
from eBioscience (San Diego, CA). Rectal temperature of the mice at
desirable time points wasmeasured using a specially designed Thermo-
couple Meter from Kent Scientiﬁc Corp (Torrington, CT).
2.3. Evaluation of glucose homeostasis and insulin sensitivity
Insulin concentrations were determined using a Mercodia Insulin
ELISA kit from Mercodia Developing Diagnostics (Winston Salem, NC)
following the provided protocol. For the glucose tolerance test (GTT),
mice were injected intraperitoneally with glucose at 1.5 g/kg body
weight after 6 h fasting. Blood samples were taken at varying time
points and glucose concentrations were determined using glucose test
strips and TUREtrack glucose meters from Nipro Diagnostics Inc.
(Fort Lauderdale, FL). For the insulin tolerance test (ITT), mice fasted
for 4 h and blood glucose levels were measured after an intraperitoneal
injection of insulin (0.75 U/kg) from Eli Lilly (Indianapolis, IN).
HOMA-IR values were calculated based on the formula: (fasting insulin
[μU/ml] × fasting glucose [mmol/l])/22.5.
2.4. Histochemical and Oil Red O analysis
After mice were sacriﬁced, the liver, WAT, and BAT were collected,
ﬁxed in 10% formalin and embedded in parafﬁn. Hematoxylin and
eosin (H&E) staining was performed using tissue sections at a thickness
of 6 μm. Frozen liver sections (8 μm) were stained with 0.2% Oil Red O
reagent (ElectronMicroscopy Sciences, Hatﬁeld, PA) in 60% isopropanolfor 15 min, washed three times with phosphate buffered saline and
counter-stained with hematoxylin for 1 min. A microscopic examina-
tion was performed and photographs were taken under a regular light
microscope.
2.5. Blood and hepatic lipid analysis
A quantitative determination of liver lipidswas performed following
an established procedure [19,20]. Brieﬂy, liver tissues (100–200 mg)
were homogenized in phosphate buffered saline (1 ml), mixed with
5ml of organic solvent (chloroform:methanol= 2:1, vol/vol) and incu-
bated overnight at 4 °C. The mixture was centrifuged and the organic
phase collected. The collected fraction was dried and lipids were re-
dissolved in 1% Triton X-100. The amounts of cholesterol, triglyceride
(Thermo Fisher Scientiﬁc Inc., Waltham, MA) and free fatty acids
(Wako Bioproducts, Richmond, VA) were determined following the
manufacturers' instructions. The same kits were also used for blood
lipid analysis.
2.6. Gene expression analysis by real time PCR
Total RNA was isolated from mouse livers, the pancreas, WAT and
BAT using the TRIZOL reagent (Life Technologies, Grand Island, NY) or
RNeasy Lipid Tissue Mini Kit (QIAGEN, Valencia, CA) according to the
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for the ﬁrst strand cDNA synthesis using a First-strand cDNA Synthesis
System from OriGene (Rockville, MD). Real time PCR was performed
in an ABI StepOne Plus Real Time PCR system (Foster City, CA) using
PerfeCTa® SYBR® Green FastMix (Quanta BioSciences, Gaithersburg,
MD) as the indicator. PCR was carried out for 40 cycles at 95 °C for
15 s and 60 °C for 1min. The datawere analyzed using theΔΔCtmethod
and normalized to internal control of GAPDH mRNA. Primers were
synthesized at Sigma (St. Louis, MO). All primer sequences employed
are summarized in Table 1. Melting curve analysis of all real-time PCR
products was conducted and showed a single DNA duplex.
2.7. Western Blotting analysis
Tissue samples were homogenized on ice using a Tissue Tearor in
1 ml lysis buffer (25 mM Tris–HCl, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS, pH 7.6) with a protease inhibitor cocktail from
Millipore (Billerica, MA). The tissue homogenates were centrifuged at
12,000 rpm for 10 min and total proteins were extracted from the
supernatant. Fifty micrograms of proteins was separated on a 7.5%
SDS-polyacrylamide gel and transferred onto a polyvinylidene
diﬂuoride membrane using a Bio-Rad Mini-Blot transfer apparatus
(Richmond, CA). Membranes were blocked in a Tris-buffered solution
containing 5% non-fat milk for 1 h. Immunoblotting was performed at
4 °C overnight with shaking using antibodies against UCP1, PGC1α
from Abcam (Cambridge, MA), STAT3, p-STAT3, AMPK, p-AMPK, ACC,
p-ACC from Cell Signaling (Boston, MA) or GAPDH from Santa Cruz
Biotechnology (Santa Cruz, CA), respectively. After washing, the
membranes were incubated in a 1:3000 dilution of a secondary
antibody at room temperature for 1 h in Tris-buffered solution contain-
ing 0.5% of Tween-20. Protein bands were visualized using Pierce ECL
Western Blotting substrate (Rockford, IL).
2.8. Statistical analysis
A statistical analysis was performed using the Student's t test. All
data are reported as mean ± standard deviation (SD) with statistical
signiﬁcance set at P b 0.05.Fig. 1. Effects of hydrodynamic Il-6 gene transfer on C57BL/6 obese mice. C57BL/6 obese mice (
empty plasmidDNA. (A) Circulating IL-6 levels as a function of time; (B) Il-6mRNA level in differ
Il-6 gene expression; (D) Weight change in obese mice; (E) Representative images of mice at t
times; and (H) Food intake. Results represent mean ± SD (n = 10) for each group. *P b 0.05, *3. Results
3.1. Prolonged Il-6 gene expression induces weight loss in
C57BL/6 obese mice
The level and time-dependent Il-6 gene expression after hydrody-
namic delivery of 1 μg of pLIVE-IL6 plasmids was examined in obese
mice fed an HFD. Results in Fig. 1A show that blood concentration of
IL-6 protein reached the peak level (~10ng/ml) 1 day after gene transfer
and declined slightly with time. Six weeks after gene transfer, circulat-
ing IL-6 level remained at approximately 1 ng/ml, 50-fold higher than
that of control mice (~20 pg/ml) injected with empty plasmid. PCR
analysis revealed the highest level of Il-6 gene expression in the liver,
120-fold higher than the background level in control animals (Fig. 1B).
A slight increase of mRNA level was also seen in BAT and skeletal mus-
cle. Blood chemistry tests showed no increase of serum concentrations
of AST and ALT in animals with Il-6 gene transfer at the end of 6-week
experiment (Fig. 1C). These results prove that Il-6 gene expression can
be successfully achieved and sustained after hydrodynamic gene
delivery.
The therapeutic effect of prolonged Il-6 gene expression on obese
mice is shown in Fig. 1D and E. A slight decrease in body weight was
seen immediately after plasmid injection in both treated and control an-
imals due to effect of the procedure. However, animals injected with
pLIVE-IL6 plasmid continued to lose weight and eventually reached a
steady state with an average body weight of 38 g in 6 weeks, losing an
average of 12 g of their initial body weight of 50± 2 g. In contrast, con-
trolmice regained the bodyweight initially lost and gained an addition-
al 2 g by the end of the experiment. The analysis of body composition by
magnetic resonance imaging (MRI) revealed that weight loss in animals
with Il-6 gene transfer is fully correlated to the time-dependent de-
crease in fat mass (Fig. 1F), not lean mass (Fig. 1G). No change in fat
and lean mass was observed in control animals. Moreover, the loss of
body weight is not correlated to food intake (Fig. 1H). In addition,
body fat reductionwas further determined byweighing fat pads. Results
in Fig. 2A and B show that Il-6 gene transfer signiﬁcantly reduced the
size of fat pads including subcutaneous (subWAT), epididymal
(epiWAT) and retroperitoneal (retroWAT) adipose tissues in obesemale, 50 ± 2 g) were hydrodynamically injected via tail vein of 1 μg of pLIVE-IL6 or pLIVE
ent tissues 6weeks after gene transfer; (C) PlasmaAST and ALT levels at the end of 6-week
he end of the experiment; (F, G) Body composition of fat mass and lean mass at different
*P b 0.01, comparing to control mice injected with pLIVE empty plasmid.
Fig. 2. IL-6 reduced fat tissues depots and the size of adipocytes in obesemice. Obesemicewere sacriﬁced at the end of the 6-week after gene transfer and different fat padswere collected
and weight determined. Tissues were ﬁxed in 10% neutral buffered formalin. H&E staining was performed to show the morphology of adipose tissues. (A) Appearance of subcutaneous
(subWAT), epididymal (epiWAT) and retroperitoneal (retroWAT) fat tissues collected from obese mice; (B) Weight of fat pads in (A); (C) Representative images of H&E staining of
subWAT, epiWAT and retroWAT (100×); and (D) Average diameter of adipocytes in different fat pads (calculated from 200 adipocytes from 4 separate slides). Results represent
mean ± SD. *P b 0.05, **P b 0.01, comparing to control obese mice injected with pLIVE empty plasmid.
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adipocytes in subWAT, epiWAT and retroWAT showed reduced size of
adipocytes (Fig. 2C), which was also conﬁrmed by quantiﬁcation analy-
sis using an imaging system (Fig. 2D).
To examine whether Il-6 gene transfer only affects fat mass, we
performed the same set of experiments in age-matched chow-fed
mice. The expression of Il-6 gene after hydrodynamic gene delivery
slightly reduced body weight of normal mice by 2.5 g due to re-
duced fat mass, but not lean mass (Fig. 3A, C and D). Again, Il-6
gene transfer did not affect food intake in mice fed a regular chow
(Fig. 3B). Taken together, these data demonstrate that prolonged
Il-6 gene expression reduces body weight and fat mass without
affecting food intake.
3.2. Sustained IL-6 level alleviates hepatic steatosis in obese mice
Obese mice displayed an extensive vacuolation in H&E stained
liver section (Fig. 4A), indicating severe fat accumulation in the
liver. Il-6 gene transfer dramatically reduced fat accumulation in
the liver, as evidenced by the recovered normal liver structure
(Fig. 4A) and fewer lipid droplets stained by Oil Red O (Fig. 4B).
Consistent with these results, Il-6 gene transfer signiﬁcantlyreduced hepatic triglyceride, total cholesterol and free fatty acid
levels in obese animals (Fig. 4C–E). Il-6 gene transfer also reduced
blood concentrations of free fatty acid, but not triglyceride levels
(Fig. 4F–H).
A real time PCR analysis was carried out to evaluate the effect of
Il-6 gene transfer on the expression of genes involved in hepatic fat
accumulation. Fig. 5A shows that Il-6 gene transfer markedly sup-
pressed mRNA levels of peroxisome proliferator-activated receptor
gamma (Pparγ1) (42%), Pparγ2 (83%), and their target genes, in-
cluding Cd36 (71%), fatty acid binding protein 4 (Fabp4, 46%), and
monoacylglycerol O-acyltransferase 1 (Mgat1, 99%). At the end of
the 6-week experiment, IL-6 did not affect Pparα and its target
genes including carnitine palmitoyl-transferase I (Cpt1) and perox-
isomal acyl-coenzyme A oxidase 1 (Acox1) (Fig. 5B). IL-6 also did
not signiﬁcantly affect hepatic lipogenic genes with the exception
of reducing fatty acid synthase (Fas) gene expression by 46%. In
regard to cholesterol metabolism, IL-6 enhanced 3-hydroxy-3-
methylglutaryl coenzyme A reductase (Hmgcr) gene expression by
2 fold and increased cholesterol 7 α-hydroxylase (Cyp7a1) gene ex-
pression by 4.3 fold (Fig. 5C). Collectively, these data demonstrate
that prolonged Il-6 gene expression alleviates obesity-associated
fatty liver.
Fig. 3. Elevation of Il-6 gene expression in age-matched chow-fed C57BL/6mice decreased the fatmass. Onemicrogram of pLIVE-IL6 or pLIVE empty plasmidwas delivered to each chow-
fed C57BL/6malemouse through a hydrodynamic-based procedure. (A) Growth curve; (B) Food intake; and (C, D) Fatmass and leanmass at different times. Results representmean±SD
(n = 5) for each group. *P b 0.05, **P b 0.01, comparing to control mice injected with pLIVE empty plasmid.
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homeostasis in obese mice
To address the impact of Il-6 gene transfer on insulin sensitivity and
glucose homeostasis, we monitored blood insulin levels and pancreatic
insulin gene expression. IL-6 dramatically suppressed obesity-induced
hyperinsulinemia by 78% (Fig. 6D). Accordingly, pancreaticmRNA levels
of Insulin1 and Insulin2 genes were markedly lower in mice with Il-6
gene transfer compared to control obese animals (Fig. 6E, F). In the
meantime, a glucose tolerance test (Fig. 6A) and calculated area under
the curve (AUC, Fig. 6B) revealed a lower peak level and much higher
clearance rate of intra-peritoneally injected glucose in animals with
Il-6 gene transfer. Moreover, mice with Il-6 gene transfer were more
sensitive to insulin than control obese mice when tested using an insu-
lin tolerance test (Fig. 6C), and improved insulin sensitivity was also
reﬂected by reduction in calculated HOMA-IR (Fig. 6G), the assessment
index of insulin resistance. Taken together, these data indicate that Il-6
gene transfer improves insulin sensitivity and glucose homeostasis in
obese mice.3.4. IL-6 treatment enhances lipolysis and stimulates thermogenesis
in obese mice
IL-6 has been shown to increase energy expenditure by stimulating
the function of brown adipose tissue (BAT) [13,21]. Result in Fig. S1
shows that IL-6 increased the body temperature by 0.8 °C 1 day after
gene transfer followed by a gradual decline thereafter, suggesting en-
hanced energy expenditure. H&E stained BAT showed a dramatic reduc-
tion in lipid droplets and the density of vacuole type structures (Fig. 7A).
Data in Fig. 7B show that IL-6 increased the expression of genes involved
in lipid utilization and thermogenesis in BAT including the fatty
acid transporter gene (Cd36, ~1.6-fold), hormone-sensitive lipase(Hsl, ~2.2-fold), and adipose triglyceride lipase (Atgl, ~5.4-fold). IL-6
also elevated the expression of genes responsible for fatty acid oxidation
(Cpt1, ~2.0-fold) and thermogenesis in BAT, as reﬂected by increased
thermogenic genes including Ucp1 (~1.9-fold), Ucp2 (~1.6-fold), Ucp3
(~4.8-fold), Pgc1 (~2.0-fold), Cidea (~2.6-fold), and Elovl3 (~3.5-fold).
Moreover, a Western Blotting analysis (Fig. 7C) conﬁrmed that IL-6 sig-
niﬁcantly activated its signalingmolecule of STAT3 in BAT, as evidenced
by a 3-fold increase in the ratio of the p-STAT3 to STAT3 (Fig. 7D). Con-
sequently, higher IL-6 levels enhanced protein levels of PGC1α and
UCP1, two key effectors in thermogenesis (Fig. 7E). In addition, Il-6
gene transfer increased the expression of Hsl, Atg, Cpt1 in subcutaneous
WAT (Fig. 8A–B).
Skeletal muscle is another tissue capable of utilizing fatty acids. As
shown in Fig. 9A and B, IL-6 stimulated phosphorylation of STAT3 in
skeletal muscle by 1.6-fold, indicating its potential function in muscle.
We found that IL-6 stimulated the phosphorylation of AMPK, a master
regulator for fatty acid oxidation [22], and its downstream target
acetyl-CoA carboxylase (ACC) in skeletal muscle (Fig. 9A, C and D).
Results shown in Fig. S2 demonstrate that mRNA levels of peroxisomal
acyl-coenzymeAoxidase 1 (Acox1), Cpt1a, Cpt1b and long-chain speciﬁc
acyl-CoA dehydrogenase (Acadl) gene were signiﬁcantly increased in
animals with Il-6 gene transfer. In the meantime, the mRNA levels of
Ucp3 and Pgc1α were also elevated by ~2.0-fold and ~3.0-fold, respec-
tively, suggesting that IL-6 has enhanced lipid utilization in skeletal
muscle.
3.5. Sustained IL-6 treatment did not affect macrophage inﬁltration,
but increased the M2 macrophage population in adipose tissue and liver
Finally, we examined the effect of Il-6 gene transfer on macrophage
inﬁltration and inﬂammatory response in BAT, WAT and liver tissue
(Fig. 10). IL-6 did not reduce existing macrophages, although it did dra-
matically reduce chemo-attractantMcp-1 gene expression in all tested
Fig. 4. IL-6 improves obesity-induced fatty liver.Micewere sacriﬁced at the end of 6weeks after hydrodynamic gene transfer and liverswere collected. (A) Image of liver structure by H&E
staining; (B) Images of liver sections stained for lipid distribution with red oil O staining; (C–E) Triglyceride, free fatty acid and total cholesterol contents in the liver; and (F–H) Serum
concentrations of triglyceride, free fatty acid and cholesterol 6 weeks after gene transfer. Each data point represents the mean ± SD of 6 animals in each group. *P b 0.05, **P b 0.01
compared to control group.
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M2 macrophage marker genes such as Cd163 and Cd206 in BAT,
subWAT and the liver. In the meantime, IL-6 evidently enhanced the
transcript levels of anti-inﬂammatory Il-10 and M2-related factor Il-4,
Il-13 and their receptors. Taken together, these results suggest that
IL-6 counterbalances obesity-associated pro-inﬂammation by increas-
ing M2 macrophage population and the level of anti-inﬂammatory
factors.
4. Discussion
In the current study, we examined the long-term effects of Il-6 gene
transfer on obesity and related metabolic syndromes and explored the
potential molecular mechanisms. Our results show that sustained Il-6
gene expression can be achieved in obesemice via themethod of hydro-
dynamic gene delivery, resulting in reduction of body weight and fat
mass (Figs. 1 and 2), alleviation of hepatic steatosis (Fig. 4), and im-
provement of glucose homeostasis (Fig. 6). These beneﬁcial effects
were associated with elevated lipid mobilization in WAT and enhanced
thermogenesis in BAT (Figs. 7, 8). IL-6 did not reduce obesity-related
macrophage inﬁltration, but signiﬁcantly increased expression of M2
macrophage markers and anti-inﬂammatory factor genes (Fig. 10).
Reduction in body weight by hydrodynamic Il-6 gene transfer is not
caused by reduction in food intake (Fig. 1H). This conclusion is in agree-
ment with previous study where adeno-associated viral vector was
used to deliver the Il-6 gene into the hypothalamus in rats [13]. It wasshown that AAV-mediated Il-6 gene transfer suppressed weight gain
of animals and the visceral adiposity but did not affect food intake in a
period of 5weeks. However, intracerebroventricular injection of recom-
binant IL-6 protein at 0.4 μg/day resulted in reduction in food intake per
body weight [15] but not at 100–200 ng level [4], suggesting critical
impact of IL-6 dose on animal appetite.
Slight, but signiﬁcant, elevation in body temperature by Il-6 gene
transfer (Fig. S1) suggests that an IL-6 mediated reduction in fat mass
can be attributed to its action in stimulating thermogenesis and lipid
utilization in BAT. Li et al. reported that an increase in central IL-6 levels
stimulated the function of BAT and increased Ucp1 expression and heat
production [13].Moreover, transplanted BAT controlsmouse body com-
position andmetabolism through an increase in circulating IL-6 [22], in-
dicating that peripheral elevation of IL-6 is capable of exerting its
beneﬁcial role. In addition, hydrodynamic injection-mediated Il-6 gene
transfer greatly enhanced multiple thermogenic gene expression,
including Ucp, Pgc1α, Pgc1β, Cidea and Elovl3 (Fig. 7C). Furthermore,
promotion of phosphorylated STAT3, a master molecule in the IL-6 sig-
naling pathway and elevation of PGC-1α and UCP1 proteins in BAT
further conﬁrm that IL-6 stimulated BAT function (Fig. 7D–F).
Different from BAT, WAT is the major organ in lipid storage.
Sustained Il-6 gene expression resulting from hydrodynamic gene
transfer dramatically reduced epi-, sub-, and retro-WAT pad size
(Fig. 2), suggesting that IL-6 promotesWAT lipolysis, which contributes
to whole body weight loss. In fact, in vitro studies using 3T3-L1 pre-
adipocytes and isolated human adipocytes have shown that IL-6
Fig. 5. Effect of Il-6 gene transfer on hepatic lipidmetabolism in obesemice. After HFD-feeding obesemicewere sacriﬁced at the end of 6weeks after gene transfer, total RNA from the liver
was extracted and the relativemRNA levels of selected genes were analyzed by real time PCR. (A) Nuclear receptor genes for metabolic homeostasis, Pparγ1, Pparγ2 and the target genes
Cd36, Fabp4 andMgat1; (B) Genes involved in fatty acid oxidation, Pparα, Cpt1a, Cpt1b and Acox1; and (C) Genes involved in lipogenesis and cholesterol metabolism, Srebp1-c, Acc1, Fas,
Scd-1, Hmgcr and Cyp7a1. Each data point represents the mean ± SD (n = 4). *P b 0.05, **P b 0.01 compared to control group.
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further prove that the infusion of recombinant IL-6 increased lipolysis
and fat oxidation [25,26]. In line with these studies, our results showFig. 6. IL-6 improves insulin sensitivity and glucose homeostasis in obesemice. (A) Time-depend
the curve from glucose tolerance test; (C) Time-dependent ratio of glucose concentration upon
transfer; (E, F) mRNA levels of insulin 1 and insulin 2 in pancreas at the end of 6 weeks after g
*P b0.05, **P b 0.01 compared to control animals.that prolonged overexpression of the Il-6 gene signiﬁcantly enhances
transcript levels of Hsl and Atgl in sub-WAT (Fig. 8A), the key enzymes
involved in lipolysis. In the meantime, IL-6 also enhanced fatty acident blood concentration of glucose upon i.p. injection of glucose (1.5 g/kg); (B) Area under
i.p. injection of insulin (0.75 units/kg); (D) Insulin level at the end of 6 weeks after gene
ene transfer; (G) HOMA-IR values. Each data point represents the average ± SD (n = 6).
Fig. 7. Il-6 gene transfer stimulated thermogenic activity in obesemice. (A) Representative images of H&E staining of BAT (200×); (B) Relative mRNA levels of genes involved in lipolysis,
fatty acidβ-oxidation or thermogenesis in BAT (n=4); (C) Phosphorylation of STAT3, total STAT3, PGC1α andUCP1proteins in BAT determined byWesternBlotting (n=3); (D) Relative
ratio of P-STAT3 to STAT3 based on the results of (C); (E) Change of PGC1α and UCP1 protein level in BAT. Each data point represents the average± SD. *P b 0.05, **P b 0.01 compared to
control animals.
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Moreover, IL-6 increased transcription of thermogenic genes in WAT
(Figs. 8A, B), indicating its potential capability in WAT remodeling.
Skeletal muscle is an important organ involved in lipid metabolism.
Therefore, we investigated the effect of Il-6 gene transfer on lipid me-
tabolism in skeletal muscle. A Western Blotting analysis showed that
prolonged Il-6 gene expression stimulated STAT3 and AMPK activation,
consequently enhancing phosphorylation of ACC (Fig. 9A–D). AMPK is
well documented to phosphorylate ACC, a rate-limiting step in the con-
version of acetyl-CoA to malonyl-CoA. The phosphorylation of ACC in-
hibits its activity, leading to a decrease in malonyl-CoA and an
increase in transferring long-chain fatty acyl-CoA into mitochondria
for oxidation. In agreementwith these results, other researchers also re-
ported that short-term administration of IL-6 promotes lipid metabo-
lism in rat and human skeletal muscle [27,28]. Overall, these resultsFig. 8. IL-6 stimulates white adipocyte remodeling in obese mice. At the end of 6 weeks afte
thermogenesis were determined in the subcutaneous (A) and epididymal (B) fat tissues by
*P b 0.05, **P b0.01 compared to control animals.demonstrate that sustained high levels of IL-6 resulting from hydrody-
namic gene delivery stimulates lipolysis inWAT and promotes thermo-
genesis and lipid metabolism in BAT and skeletal muscle, consequently
resulting in improvement of insulin resistance.
Several lines of studies have indicated that IL-6 exerts the protective
role in various hepatic diseases. IL-6 stimulates liver regeneration and
protects against liver injury [29,30]. Similarly, IL-6 is capable of
correcting ethanol-induced hepatic steatosis in IL-6 deﬁcient mice
[31]. Moreover, 10 days of subcutaneous IL-6 injection ameliorates the
fatty liver in genetic and diet-induced obese mice [32]. Concordance
with these reports, Il-6 gene transfer in our study dramatically reduced
lipid accumulation as demonstrated by H&E and Oil Red O stained-liver
sections andmeasured hepatic lipid levels (Fig. 4A–E). At themolecular
level, IL-6markedly suppressedmRNA levels of Pparγ and their targeted
genes including Cd36, Fabp4 and Mgat1 (Fig. 5A). PPARγ plays anr gene delivery, mice were sacriﬁced. The mRNA level of genes involved in lipolysis and
real time PCR. Each data point represents the average ± SD of 4 animals in each group.
Fig. 9. Effect of IL-6 on fat oxidation in skeletalmuscle of obesemice. Aftermice were sacriﬁced at the end of experiment, the gastrocnemius and soleusmuscleswere freshly collected and
immediately frozen in liquid nitrogen, and then stored at−80 °C. (A)Western Blotting analysis for total and phosphorylated STAT3, AMPK and ACC, as well as GAPDH; (B–D) The ratios of
phosphorylated and the native forms of these proteins based on scanning image of (a). *P b 0.05, **P b 0.01 compared to control group (n = 3).
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of hepatic Pparγ results in exacerbated liver steatosis [33]. Conversely,
liver- and hepatocyte-speciﬁc Pparγ knockout mice were protected
against hepatic lipid accumulation [34–36]. Therefore, the inhibition ofFig. 10. Effect of Il-6 gene transfer onmRNA levels of macrophage speciﬁc marker genes. Micew
real time PCRwas performed to detectmRNA levels of macrophagemarker genes. General macr
Il-1β,Mcp-1; and M2-macrophagemarker genes, Cd163, Cd206, Il-10, Il-4, Il-13, and their recep
represents the average ± SD of 4 animals in each group. *P b 0.05, **P b 0.01 compared to conhepatic PPARγ pathway is responsible, at least in part, for its beneﬁ-
cial effect on hepatic steatosis. In addition, short-term IL-6
administration has been reported to increase hepatic PPARα and
fatty acid oxidation [32]. However, we did not see a change inere sacriﬁced at the end of experiment. The liver,WAT and BAT tissues were collected and
ophagemarker genes: F4/80 and Cd68;M1-macrophagemarker genes: Cd11b, Cd11c, Tnfα,
tor genes Il-4rα, Il-13rα1. (A) liver; (B) subWAT; (C) epiWAT and (D) BAT. Each data point
trol animals.
1010 Y. Ma et al. / Biochimica et Biophysica Acta 1852 (2015) 1001–1011Pparα transcript levels and its target gene after the 6-week treat-
ment (Fig. 5B), suggesting that activation of PPARα is important for
mediating short-term effects of IL-6, but may not be necessary for
long-term IL-6 effects.
The role of IL-6 in insulin resistance remains debatable. Addition of
IL-6 to HepG2 cells in culture and acute infusion of IL-6 in mice showed
impaired insulin signaling and insulin sensitivity [37,38]. However, ac-
cumulating in vivo studies show the protective role of IL-6 in glucose
homeostasis. IL-6 deﬁcient mice and animals with hepatic disruption
of IL-6 signaling pathway develop system insulin resistance [12,39].
Whereas IL-6 transgenic mice displayed higher sensitivity to insulin
[10]. In our study, Il-6 gene transfer greatly repressed diet-induced
hyperglycemia and hyperinsulinemia. IL-6 quickly reduced obesity-
induced high blood glucose levels and consistently kept it at normal
levels throughout the experiment. IL-6 evidently enhanced insulin
sensitivity, as reﬂected by GTT, ITT and reduced HOMA-IR (Fig. 6A–C).
Accordingly, obesity-induced hyperinsulinemia and increased expres-
sion of pancreatic insulin genes were dramatically reduced (Fig. 6D–F).
Similarly, reduction in adiposity and enhanced lipid utilization by Il-6
overexpression also improve glucose homeostasis. In addition, a recent
study has shown that IL-6 is capable of stimulating glucagon-like
peptide-1 secretion from L cells and alpha cells, enhancing insulin secre-
tion and reaction [40], whichmay also contribute to the beneﬁcial effect
of IL-6 on glucose metabolism. Taken together, our study supports the
notion that IL-6 alleviates obesity-related insulin resistance and
improved glucose homeostasis.
Macrophage inﬁltration is a common feature in HFD-induced
obesity. A previous study shows that HFD induces a shift of macro-
phage phenotype from a M2-polarized state in lean animals to a
M1 pro-inﬂammatory state, characterized by high mRNA level of
marker gene such as F4/80 and CD11c, and higher level of pro-
inﬂammatory cytokines [41]. Our results show that IL-6 did not re-
duce themacrophage inﬁltration. However, IL-6markedly enhanced
M2 macrophage phenotype, as evidenced by higher mRNA levels of
Cd163 and Cd206, anti-inﬂammatory factor Il-10, stimulator Il-4, Il-
13 and their receptor genes (Fig. 10A–D). M2 macrophages are gen-
erally associated with tissue surveillance and enhanced sensitivity
to insulin. Recent studies reported that type 2 cytokines, such as
IL-4 and IL-13, and alternatively activatedmacrophages are involved
in adaptive thermogenesis and beige cell production, suggesting the
important and beneﬁcial role of M2macrophages in obesity [42–44].
In line with our study, Mauer et al. [45] have shown that a
conditionally inactivated IL-6 receptor α in myeloid cells increased
systemic inﬂammation, while administration of IL-6 enhanced IL-4
receptor expression and promoted IL-4 mediated alternative
activation of macrophages, which consequently limited obesity-
associated chronic inﬂammation and insulin resistance, as well as
LPS-stimulated endotoxemia. Overall, our data suggest that IL-6
treatment in obese mice counterbalances the obesity-related pro-
inﬂammation by elevation of M2 phenotype of macrophages.
In summary, results presented in this study demonstrate that
sustained Il-6 gene expression in obese mice, achieved by hydrody-
namic gene delivery, enhances lipolysis and thermogenesis, and
consequently induces weight loss and diminishes obesity-related
fatty liver and insulin resistance. These ﬁndings provide direct evi-
dence in support of the potential health beneﬁts of IL-6 in managing
obesity and obesity-associated metabolic disorders. Evidently, addi-
tional efforts are needed to deﬁne the factors that are possibly in-
volved in the process. Additional studies are also needed to assess
the potential side effects that IL-6 may induce due to its function
as a pro-inﬂammatory cytokine. Considering the relative smaller
BAT depots in human and the difference between mice and human
in energy metabolism and thermogenesis, caution should be taken
when applying the presented results to humans.
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